Items Tagged ‘tafinlar’

July 25th, 2014

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover


An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped early so that those receiving Zelboraf could cross over and begin taking the combination therapy instead. The committee made the recommendation after an interim analysis […]

View full entry

Tags: mekinist, Melanoma, News, Stage III Melanoma, Stage IV Melanoma, tafinlar, zelboraf